Genentech USA has been granted a patent for a method of administering Compound I to treat fibrotic, inflammatory, or autoimmune disorders. The therapy aims to address these conditions in subjects in need. GlobalData’s report on Genentech USA gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Genentech USA Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Genentech USA, was a key innovation area identified from patents.

Treatment method for fibrotic, inflammatory, or autoimmune disorders using compound i

Source: United States Patent and Trademark Office (USPTO). Credit: Genentech USA Inc

The granted patent (Publication Number: US11925624B2) discloses a method for providing Compound I therapy to a subject in need. The method involves evaluating the subject's renal function, specifically by determining the creatinine clearance rate. Different creatinine clearance ranges are specified, from =90 mL/min to 15-29 mL/min, indicating varying levels of renal function. Importantly, the method excludes subjects with end-stage renal disease requiring dialysis, ensuring the therapy's suitability for specific renal conditions.

Additionally, the method includes monitoring changes in the subject's serum creatinine level post-therapy administration. Based on these changes, adjustments to the Compound I dosage or discontinuation of therapy may be recommended. Notably, specific criteria are outlined for advising the subject to discontinue Compound I therapy, such as a significant increase in serum creatinine levels. Furthermore, the patent specifies that the subject targeted for this therapy is suffering from a fibrotic disorder, with a particular mention of idiopathic pulmonary fibrosis (IPF). This targeted approach highlights the potential efficacy of Compound I therapy in managing fibrotic conditions, particularly IPF, showcasing a specialized treatment method for these specific medical conditions.

To know more about GlobalData’s detailed insights on Genentech USA, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies